Home / Precision Medicine

Precision Medicine

Gottlieb Makes Statement on FDA’s New Steps to Modernize Drug Development, Improve Efficiency and Promote Innovation of Targeted Therapies

The FDA continues to advance new policies, modernize our programs and advance opportunities for developing more targeted therapies. Using new technology platforms such as cell and gene therapies and small molecule drugs that target the genomic basis of disease, there are more opportunities to intervene in the underlying mechanisms that cause a …

Read More »

Myriad Announces New GeneSight Study Published in Personalized Medicine

SALT LAKE CITY, Sept. 26, 2018 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a worldwide leader in personalized medicine, today announced that a health economic study to evaluate the financial impact of the GeneSight® combinatorial pharmacogenomic (CPGx) test on major commercial health plans was published in the journal Personalized Medicine.  The …

Read More »

Gilead and Precision BioSciences Collaborate to Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing

FOSTER CITY, Calif. & DURHAM, N.C.–(BUSINESS WIRE)–Gilead Sciences (Nasdaq: GILD) and Precision BioSciences announced today that the companies have entered into a strategic collaboration to develop therapies targeting the in vivo elimination of hepatitis B virus (HBV) with Precision’s proprietary genome editing platform, ARCUS. An estimated 257 million people are living with …

Read More »

Ferring and Celmatix Partner to Advance Care in Reproductive Medicine and Accelerate Development of Personalized Interventions

SAINT-PREX, Switzerland & NEW YORK–(BUSINESS WIRE)–Ferring Pharmaceuticals and Celmatix today announced an ambitious genomics collaboration aimed at uncovering new insights into ovarian biology and accelerating the development of personalized interventions in reproductive medicine and women’s health. This collaboration will leverage both Ferring and Celmatix’s significant expertise in women’s reproductive health …

Read More »

Vertex and Genomics plc Collaborate to Use Human Genetics and Data Science to Advance Discovery of Precision Medicines

BOSTON & OXFORD, United Kingdom–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Genomics plc today announced a three-year collaboration, extendable to five years, to use human genetics and machine learning to improve discovery of targets for precision medicines, and to advance understanding of the clinical impact of human genetic variation and …

Read More »

Novartis’ Investigational PI3K inhibitor Meets Primary Endpoint in Phase 3 Breast Cancer Trial

Basel, August 23, 2018 – Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint showing an improvement in progression-free survival (PFS). SOLAR-1 is evaluating BYL719 in combination with fulvestrant compared to fulvestrant alone in postmenopausal women and men with …

Read More »

ArQule Announces Publication of Preclinical Data for ARQ 531, a Reversible Inhibitor of Both Wild Type and Mutant BTK

BURLINGTON, Mass.–(BUSINESS WIRE)–ArQule, Inc. (Nasdaq:ARQL), today announced the publication of preclinical study data for ARQ 531, the Company’s rationally-designed, reversible inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK). The studies, published in Cancer Discovery, were conducted in collaboration with researchers at The Ohio State University. Data from …

Read More »

Premier Partners with Progknowse to Develop Precision Medicine Analytics

CHARLOTTE, N.C. & TYSONS, Va.–(BUSINESS WIRE)–Premier Inc. (NASDAQ: PINC), a healthcare improvement company, is partnering with Progknowse, Inc. to develop a clinical and genomic data set for use within the PremierConnect® performance improvement platform to develop new predictive analytics capabilities that support precision medicine and personalized care delivery. Premier and Progknowse …

Read More »

Foundation Medicine Publishes New Data Supporting Blood Tumor Mutational Burden as a Novel Predictor of Response to Cancer Immunotherapy

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, today announced the publication of the results of a large study demonstrating that its novel, investigational assay to measure blood tumor mutational burden (bTMB) can help predict response to the anti-PD-L1 immunotherapy, atezolizumab, (TECENTRIQ®) in patients with previously treated non-small cell lung cancer (NSCLC). The study, …

Read More »

Newly Characterized Molecule Offers Possibilities for Novel Alzheimer’s Treatments

Alzheimer’s disease is an increasingly prevalent, neurodegenerative condition that erodes memory and other cognitive functions. Treatments for this complex disease have been elusive, although researchers have previously uncovered its main biological features: amyloid-beta plaques and tau tangles. A study by researchers from Brigham and Women’s Hospital (BWH), recently published in Acta …

Read More »